Short Interest in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Increases By 601.2%

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a significant increase in short interest in February. As of February 27th, there was short interest totaling 1,274,209 shares, an increase of 601.2% from the February 12th total of 181,710 shares. Currently, 9.2% of the company’s stock are short sold. Based on an average trading volume of 2,687,153 shares, the days-to-cover ratio is presently 0.5 days. Based on an average trading volume of 2,687,153 shares, the days-to-cover ratio is presently 0.5 days. Currently, 9.2% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.33.

Institutional Trading of Kairos Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in shares of Kairos Pharma during the 2nd quarter worth approximately $44,000. Two Sigma Investments LP acquired a new stake in Kairos Pharma during the 3rd quarter worth $54,000. Finally, FNY Investment Advisers LLC acquired a new stake in Kairos Pharma during the 3rd quarter worth $27,000.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN:KAPA traded up $0.00 on Wednesday, hitting $0.64. 25,766 shares of the company’s stock were exchanged, compared to its average volume of 655,797. Kairos Pharma has a 1-year low of $0.40 and a 1-year high of $2.11. The company has a market capitalization of $13.39 million, a PE ratio of -2.07 and a beta of 2.28. The firm’s 50-day moving average is $0.70 and its 200 day moving average is $0.94.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.